What is BrainQ?
Founded in 2011 and headquartered in Israel, BrainQ is at the forefront of neuro-technology innovation. The company specializes in developing a breakthrough platform that utilizes BCI-based approaches to address complex neurological impairments. By mapping brain activity and delivering targeted, non-invasive therapies, BrainQ seeks to restore function in patients suffering from stroke, spinal cord injuries, and other neurodegenerative disorders. Their market position is defined by a unique intersection of deep-tech engineering and clinical neurology, positioning them as a high-growth entity within the global digital health landscape.
How much funding has BrainQ raised?
BrainQ has raised a total of $48.8M across 2 funding rounds:
Unspecified
$8.8M
Unspecified
$40M
Unspecified (2018): $8.8M with participation from OurCrowd.com, Qure Ventures, Norma Investments, Amir Gross, and IT-Farm
Unspecified (2021): $40M led by Hanaco, Peregrine Ventures, and Dexcel Pharma Technologies
Key Investors in BrainQ
Hanaco
Hanaco Ventures is a venture capital firm focused on supporting founders with big ideas and turning their visions into successful businesses, operating from Herzliya and New York.
Peregrine Ventures
Peregrine is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies at various stages of development.
Dexcel Pharma Technologies
Dexcel Pharma Technologies is a prominent pharmaceutical entity that provides strategic backing to innovative healthcare and life science ventures.
What's next for BrainQ?
With the recent influx of capital, BrainQ is expected to prioritize the expansion of its clinical trial pipeline and the refinement of its BCI algorithms. The strategic focus will likely shift toward regulatory milestones and the integration of its therapeutic platform into standard clinical workflows. As the company scales, it will leverage its strong investor syndicate to navigate the complexities of the global healthcare market, aiming to establish its BCI-based therapy as a standard of care for neurological rehabilitation. The focus remains on translating research-grade innovation into scalable, patient-centric solutions that address the significant unmet needs in the neurology sector.
See full BrainQ company page
